Elahere demonstrates OS benefit in the phase III MIRASOL trial in FRα-positive, platinum-resistant ovarian cancer

Phase II OVATION 2 Study of IMNN-001 shows positive OS for ovarian cancer

IMUNON Inc. announced additional clinical data from ongoing analyses of results from the company’s phase II OVATION 2 Study of IMNN-001, its investigational interleukin-12 immunotherapy for the treatment of advanced ovarian cancer based on its proprietary TheraPlas technology.

December 13, 2024

Vol.50 No.46

Drugs & Targets

EC approves of Elahere for treatment of platinum-resistant ovarian cancer

EC granted marketing authorization for Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. Elahere is the first and only folate receptor alpha-directed antibody drug conjugate medicine approved in the EU, as well as Iceland, Liechtenstein, Norway, and Northern Ireland.

November 22, 2024

Vol.50 No.44

Drugs & Targets

LINDIS Biotech signs licensing agreement with Pharmanovia for the commercialization of catumaxomab

Lindis Biotech GmbH announced a licensing agreement with global pharmaceutical company Pharmanovia for catumaxomab, for the treatment of malignant ascites.

November 22, 2024

Vol.50 No.44

Clinical Roundup

Preclinical data show anti-CD24 macrophage checkpoint inhibitor promotes phagocytosis and shrinks tumors

New preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage “don’t eat me” signal on cancer cells, were presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The meeting is taking place both virtually and at the George R. Brown Convention Center in...

November 08, 2024

Vol.50 No.42

In Brief

Oxford team receives $800K from CRUK to create vaccine for ovarian cancer

Scientists at the University of Oxford are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 (approximately US$800,000) for the study over the next three years to support lab research into the vaccine.

October 04, 2024

Vol.50 No.37

Clinical Roundup

Data from phase I/II study shows Rina-S improves ORR for treatment of ovarian cancer

Data from the phase I/II study of Rina-S (rinatabart sesutecan), an investigational folate receptor-alpha-targeted, Topo1 antibody-drug conjugate, demonstrated a confirmed objective response rate of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every three weeks, regardless of FRα expression levels.

September 20, 2024

Vol.50 No.35

Elahere demonstrates OS benefit in the phase III MIRASOL trial in FRα-positive, platinum-resistant ovarian cancer

YOU MAY BE INTERESTED IN

Phase II OVATION 2 Study of IMNN-001 shows positive OS for ovarian cancer

EC approves of Elahere for treatment of platinum-resistant ovarian cancer

LINDIS Biotech signs licensing agreement with Pharmanovia for the commercialization of catumaxomab

Preclinical data show anti-CD24 macrophage checkpoint inhibitor promotes phagocytosis and shrinks tumors

Oxford team receives $800K from CRUK to create vaccine for ovarian cancer

Data from phase I/II study shows Rina-S improves ORR for treatment of ovarian cancer

Renew today!

Subscriber content

Never miss an issue!

Login